Jeannett Dimsits

Dr. Jeannett Dimsits is a Medical Doctor with over 24 years of comprehensive experience in clinical development, spanning both global pharmaceutical corporations and nimble biotech firms. Her 14-year tenure in Clinical Development at Novo Nordisk saw her lead critical medical teams within Trauma and Hemostasis, most notably as the medical lead for the landmark CONTROL Phase 3 trial.

Currently, Dr. Dimsits oversees the Phase 3 program at MinervaX, a Danish biotech developing a transformative maternal vaccine against Group B Streptococcus. Her role requires a multifaceted mastery of clinical trial design, drug safety, and scientific publication strategy.

Driven by a passion for improving patient outcomes through novel treatment modalities and digital health optimization, Dr. Dimsits is an ambitious and results-oriented team leader. Her expertise in critical bleeds and cardiovascular health, combined with her experience in trauma medicine, positions her as a vital advisor for complex clinical R&D projects.